LIVNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
LivaNova PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$78.14+0.56 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $4.40B
- P/E (TTM)
- 23.1
- Dividend yield
- –
LivaNova PLC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiopulmonary | $221.58M | $208.66M | $206.58M | $203.22M | $199.27M | $176.32M | $181.67M | $172.24M | $173.71M | $155.89M | $165.30M | $148.96M | 56.7% | +11.2% |
| Neuromodulation | $166.95M | $151.79M | $152.72M | $149.53M | $151.67M | $138.89M | $137.61M | $139.86M | $142.88M | $133.87M | $136.93M | $128.88M | 42.7% | +10.1% |
| Advanced Circulatory Support | – | – | – | – | – | – | – | – | – | – | $10.11M | $10.95M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuromodulation | $60.94M | $44.15M | $50.92M | $56.19M | $56.02M | $52.35M | $44.29M | $49.53M | – | – | – | – | +8.8% |
| Cardiopulmonary | $28.15M | $30.07M | $27.51M | $24.70M | $31.41M | $24.69M | $20.84M | $21.67M | – | – | – | – | -10.4% |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $199.35M | $184.68M | $191.49M | $190.45M | $188.47M | $169.16M | $175.10M | $179.83M | $179.54M | $160.62M | $173.22M | $161.58M | 51.0% | +5.8% |
| Rest of World | $109.42M | $101.93M | $94.42M | $99.62M | $97.27M | $87.99M | $85.11M | $85.48M | $87.78M | $79.95M | $74.35M | $76.40M | 28.0% | +12.5% |
| Europe | $81.82M | $75.65M | $75.02M | $67.68M | $66.78M | $59.70M | $61.62M | $52.82M | $51.26M | $54.34M | $62.56M | $48.13M | 20.9% | +22.5% |
From the segment and revenue-disaggregation notes of LivaNova's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.